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OTKA NNF 78498 
Investigation of the role of poly(ADP-ribose) polymerase-2 in SIRT1 




In the frame of the project we investigated the metabolic properties of poly(ADP-
ribose) polymerase enzymes. 
 
In PARP-1-/- animals we have detected an energy expenditure (EE) phenotype 
involving the skeletal muscle and the brown adipose tissue (BAT). Oxygen 
consumption was increased in the PARP-1-/- mice in line with higher glucose 
oxidation rate (increased RQ). In parallel, in skeletal muscle and BAT mitochondrial 
biogenesis and the number of mitochondria was enhanced. Increased EE ameliorate 
the metabolic profile of the mice (e.g. better insulin and glucose tolerance, protection 
against high fat feeding-induced obesity).  
The interplay of PARP-1 and SIRT1 lay behind the increased mitochondrial 
biogenesis. In PARP-1-/- mice due to the lack of PARP-1 PARP activity decreases 
drastically, while NAD+ levels increase (the concentration of NAM that is the 
endproduct of NAD+ decomposition does not change). In parallel with these changes 
we have detected the increase of SIRT1 activity. SIRT1 activation is capable of 
enhancing mitochondrial biogenesis through PGC-1 deacetylation. 
In HEK293T cells where PARP-1 had been depleted by shRNA or in PARP-1-/- 
MEF cells we obtained similar results, whereby upon the ablation of PARP-1 NAD+ 
levels and SIRT1 activity increase. SIRT1 depletion by shRNA hampers the 
enhancement of mitochondrial biogenesis upon PARP-1 depletion. 
Since both PARP-1 and SIRT1 are NAD+ dependent, moreover PARP-1 is 
quicker and it has higher affinity towards NAD+ then SIRT1 it seems plausible that the 
common NAD+ substrate is the link between PARP-1 and SIRT1. We would like to 
emphasize however that some gene expression effects (e.g. UCP3 induction) were 
SIRT1 independent, hence there are probably other molecular events behind the EE 
phenotype in PARP-1-/- mice. 
Upon the utilization of PARP inhibitors we experienced similar enhancement of 
EE as in the case of genetic ablation of PARP-1. When C2C12 myofibers were 
treated with PJ34 (a PARP inhibitor) we have observed the decrease in PARP 
activity and the induction of SIRT1 activity and mitochondrial biogenesis. The effects 
evoked by PJ34 were mostly SIRT1 dependent (i.e. lost upon SIRT1 ablation). 
Moreover, when mice were treated with PJ34 for 4 consecutive days we were also 
able to detect the induction of EE. (Bai et al., 2011, Cell Metab. 13(4):461-8.) 
 
In PARP-2-/- mice we observed similar changes as in PARP-1-/-. PARP-2-/- mice 
displayed higher EE then PARP-2+/+. In PARP-2-/- mice we observed lower RQ 
values then in PARP-2+/+ suggesting increased oxidization of fatty acids. Increased 
EE involved the skeletal muscle and liver of the PARP-2-/- animals and was marked 
by increased amount of mitochondria and increased mitochondrial biogenesis. 
Interestingly, while skeletal muscle was affected in both strains, the BAT was affected 
only in the PARP-1-/-, while the liver in the PARP-2-/- mice.  
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In the skeletal muscle of the PARP-2-/- mice we have observed the induction of 
the SIRT1 – PGC-1 axis. The higher level of mitochondrial biogenesis ameliorated 
the metabolic profile of the mice (e.g. better insulin tolerance, protection against high 
fat feeding). In case of SIRT1 depletion the expressional changes and the higher 
oxygen consumption rates that are responsible for the advantageous metabolic 
properties were lost. In C2C12 myofibers, where PARP-2 was depleted by shRNA we 
have observed similar effects as in vivo (higher oxygen consumption, SIRT1 
activation, higher mitochondrial content etc.). 
The mechanism of SIRT1 induction is radically different in PARP-2-/- then in 
PARP-1-/- mice.  While in PARP-1-/- mice SIRT1 induction is linked to “NAD+ sparing”, 
we did not detect increases in NAD+ upon the depletion of PARP-2. However, we 
observed the induction of SIRT1 expression upon PARP-2 ablation. Later we have 
shown that PARP-2 is a repressor of the SIRT1 promoter and binds to the -1 - -91 
region. Moreover, the region responsible for PARP-2 binding is highly conserved 
from the Xenopus to the human promoter. 
Curiously, the glucose tolerance of the PARP-2-/- mice was impaired after high 
fat feeding suggesting the dysfunction of pancreas. Indeed, the size of the 
Langerhans islands was smaller in PARP-2-/- mice (the islets were unable to undergo 
hyperplastic response). Moreover, we detected lower pancreatic insulin content in 
PARP-2-/- mice in accordance with an expression pattern indicative of beta cell 
dysfunction. Pancreas dysfunction in PARP-2-/- mice is related to SIRT1 induction 
that apparently impairs beta cell regeneration. (Bai et al, 2011, Cell Metab. 13(4):450-
60.) 
 
In our in vitro experiments we used C2C12 and HepG2 cell where PARP-2 was 
knocked down using lentiviral vectors containing a 21 nucleotide long interfering 
sequence specific for PARP-2 (shPARP-2 sequence). We designed another 
sequence of the same length and nucleotide composition that had no human or 
murine homolog (scrPARP-2). A549, C2C12 and HepG2 cells were transduced with 
the above viruses. A549 cells served as controls of transduction as their capabilities 
were determined earlier (Erdélyi et al. FASEB J, 2009). Data on the PARP-2 silenced 
C2C12 cells were detailed above. 
In shPARP-2 HepG2 cells we have observed the induction of the EE phenotype 
marked by increased mitochondrial number and mitochondrial membrane potential. 
Consequently the level of stored lipids and glycogen decreased. Currently we are 
examining the carbohydrate metabolism of the shPARP-2 HepG2 cells. 
The phenotyping of these cells began with a comprehensive analysis of gene 
expression using microarray. For the analysis we used Affymetrix GeneChip Human 
Gene 1.0 ST and GeneChip Mouse Gene 1.0 ST microarray slides (n=3/3 
scr/shPARP-2). Low values (<500) were omitted as no, or low expression genes and 
the rest was normalized. The respective values for each gene was compared (sh vs. 
scr) using a unpaired t-test after Bonferroni correction and p<0.05 was considered as 
significant. In HepG2 cells 653, while in C2C12 cells 757 genes were dysregulated 
when comparing sh and scr cells. These genes were analysed using the BINGO 
module of the Cytoscape software in order to classify the genes into biochemical 
pathways and functions. The results of the microarray have been validated in RT-
qPCR assays. 
Among multiple others we observed the induction of cholesterol biosynthesis 
enzymes. Upon examining the transcription factors driving the expression of the 
genes induced we presumed that the activation of LXR and/or SREBP-1 and -2 are 
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responsible for the above detailed effect. Validation suggested that the expression of 
SREBP-1 and -2 are induced leading to consecutive induction of HMG-CoA synthase 
and HMG-CoA reductase expression and higher intracellular cholesterol levels. 
Higher cholesterol levels were observed in shPARP-2 HepG2 cells and in PARP-2-/- 
mice. These investigations are currently being continued. 
 
We investigated the role of PARP enzymes in gene expression in a murine model 
of contact hypersensitivity (CHS). On the course of the hypersensitivity reactiony of 
the skin considerable amount of free radicals are produced that – as our previous 
studies indicated – may induce PARP activation. We have shown that PARP-1 is 
responsible for the poly(ADP-ribosyl)ation in such situations and its ablation reduces 
inflammation. In contrast, PARP-2 did not influence the CHS reaction. PARP-1 
depletion reduced neutrophyl infiltration, proinflammatory cytokine production and the 
expression of cellular adhesion molecules and MMP9 through influencing the redox-
sensitive NFB and ATF-2 transcription factors. Reducing inflammation blunts 
oxidative and nitrosative stress and hence PARP-1 activation. Our results identify 
oxidative stress and PARP-1 activation as major actors in the intensification of skin 
inflammatory processes. Furthermore we have shown that PARP-1 depletion has 
partial protective effect on irritative dermatitis. (Brunyánszki és mtsai, 2010. J Invest 
Derm 130(11):2629-37) 
 
Our group was involved on the tenure of the grant in a study investigating the role 
of PARP-1 and poly(ADP-ribose) glycohydrolase (PARG) in oxidative stress-induced 
cell death. In flow cytometry experiments we have shown that both PARP-1 and 
PARG knockdown cells are protected against hydrogen-peroxide – induced 
membrane permeabilisation and cell death. (Erdélyi és mtsai, 2009. FASEB J 
23(10):3553-63) 
 
Our major findings are as follows: 
 
- The depletion of PARP-1 and -2 enhance biological oxidation in skeletal 
muscle through inducing SIRT1 activation. 
- The depletion of PARP-1 and -2 provide protection against obesity induced by 
hypercaloric feeding. 
- PARP inhibitors evoke similar EE phenotype as PARP-1 depletion. 
- PARP-2 depletion leads to enhanced cholesterol biosynthesis and 
hypercholesterinaemia through the induction of SREPB-1 and -2 and/or LXR 
activation. 
